Aurobindo Pharma is currently trading at Rs. 596.90, up by 3.60 points or 0.61% from its previous closing of Rs. 593.30 on the BSE.
The scrip opened at Rs. 594.00 and has touched a high and low of Rs. 602.75 and Rs. 592.90 respectively. So far 29574 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 821.75 on 13-Aug-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 603.80 and Rs. 562.65 respectively. The current market cap of the company is Rs. 34763.74 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.01% and 10.15% respectively.
Aurobindo Pharma’s wholly owned subsidiary — Eugia Pharma Specialties has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials.
Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vasostrict Injection, 20 units/mL of Par Sterile Products, LLC (Par).
The product is being launched immediately. The approved product has an estimated market size of around $606 million for the twelve months ending June 2022, according to IQVIA.
This is the 146th ANDA (including 10 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like
astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.